BD and CerTest Biotec Announce Commercial Launch of Monkeypox Test

0

“One of the key benefits of the BD MAX™ System is its open architecture system that enables rapid response to emerging health threats,” said Nikos Pavlidis, vice president of molecular diagnostics at BD. “Just as we did at the start of the COVID-19 pandemic, we have partnered with CerTest to rapidly develop a molecular test to better understand and track this disease.”

The BD MAX™ System is a fully integrated and automated platform that performs nucleic acid extraction and real-time PCR providing results for up to 24 samples across multiple syndromes in less than three hours. BD offers a wide range of system tests covering healthcare associated infections, respiratory infections, sexually transmitted infections, gastrointestinal infections and women’s health. BD offers an open-system reagent suite for the BD MAX™ System that allows laboratories to fully automate and streamline their lab-developed assays.

“Speed ​​is key to responding to what the World Health Organization has declared a global health emergency,” Nelson Fernandes, CEO of CerTest Biotec. “We hope this new test will increase research capacity on monkeypox, ultimately helping to stem the spread of the disease.”

As with all CerTest assays, the Monkeypox PCR Detection Kit for the BD MAX™ System is offered in a lyophilized format. Therefore, the test will be delivered in a tube that snaps into the test-specific position on the BD MAX™ ExK™ TNA Extraction Strip, which is supplied by BD.

About comics
BD is one of the world’s largest global medical technology companies and advances the world of healthcare by improving medical discovery, diagnostics and care delivery. The company supports heroes on the front lines of healthcare by developing innovative technologies, services and solutions that help advance both clinical therapy for patients and the clinical process for healthcare providers. BD and its 75,000 employees have a passion and commitment to help improve the safety and efficiency of the clinician care delivery process, enable laboratory scientists to accurately detect disease, and advance capabilities of researchers to develop the next generation of diagnostics and therapies. BD is present in virtually every country and partners with organizations around the world to solve some of the world’s toughest health issues. By working closely with its customers, BD can help improve outcomes, reduce costs, increase efficiency, improve safety and expand access to healthcare. For more information about BD, visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

About CerTest
CerTest Biotec is a European company created in 2002 for the development and manufacture of in vitro diagnostic medical devices. Today, CerTest is a global company structured around seven business units offering one of the broadest portfolios for human in vitro diagnostics and pharmaceuticals. The company bases its future on solid technical knowledge and expertise in the detection of human diseases. State-of-the-art CerTest laboratories, state-of-the-art technical equipment and qualified professionals are the keys to providing reliable solutions to the medical diagnostic professional.

contacts:




Media:

Investors:

Troy Kirkpatrick

Francesca DeMartino

Vice President, Public Relations

SVP, Head of Investor Relations

858.617.2361

201.847.5743

[email protected]

[email protected]

COMIC SOURCE (Becton, Dickinson and Company)

Share.

Comments are closed.